500 related articles for article (PubMed ID: 28096717)
1. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in renal cell carcinoma.
Ross K; Jones RJ
Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
[TBL] [Abstract][Full Text] [Related]
5. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Assal A; Kaner J; Pendurti G; Zang X
Immunotherapy; 2015; 7(11):1169-86. PubMed ID: 26567614
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Quandt Z; Young A; Anderson M
Clin Exp Immunol; 2020 May; 200(2):131-140. PubMed ID: 32027018
[TBL] [Abstract][Full Text] [Related]
7. Clinical Development of Immune Checkpoint Inhibitors.
Ito A; Kondo S; Tada K; Kitano S
Biomed Res Int; 2015; 2015():605478. PubMed ID: 26161407
[TBL] [Abstract][Full Text] [Related]
8. Targeting Immune Checkpoints in Hematologic Malignancies.
Alatrash G; Daver N; Mittendorf EA
Pharmacol Rev; 2016 Oct; 68(4):1014-1025. PubMed ID: 27664133
[TBL] [Abstract][Full Text] [Related]
9. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Choudhury N; Nakamura Y
Cancer Sci; 2016 Feb; 107(2):107-15. PubMed ID: 26678880
[TBL] [Abstract][Full Text] [Related]
10. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
Conway JR; Kofman E; Mo SS; Elmarakeby H; Van Allen E
Genome Med; 2018 Nov; 10(1):93. PubMed ID: 30497521
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic oncolysis by tigilanol tiglate.
Pol JG; Lizarralde-Guerrero M; Kroemer G
Oncoimmunology; 2024; 13(1):2360230. PubMed ID: 38812571
[TBL] [Abstract][Full Text] [Related]
12. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
Francis DM; Thomas SN
Adv Drug Deliv Rev; 2017 May; 114():33-42. PubMed ID: 28455187
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibition: from molecules to clinical application.
Taams LS; de Gruijl TD
Clin Exp Immunol; 2020 May; 200(2):105-107. PubMed ID: 32297327
[No Abstract] [Full Text] [Related]
14. A novel mouse model for checkpoint inhibitor-induced adverse events.
Adam K; Iuga A; Tocheva AS; Mor A
PLoS One; 2021; 16(2):e0246168. PubMed ID: 33571254
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.
Abdou Y; Pandey M; Sarma M; Shah S; Baron J; Ernstoff MS
Br J Clin Pharmacol; 2020 Sep; 86(9):1690-1702. PubMed ID: 32323342
[TBL] [Abstract][Full Text] [Related]
16. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Keung EZ; Ukponmwan EU; Cogdill AP; Wargo JA
Ann Surg Oncol; 2018 Jul; 25(7):1814-1827. PubMed ID: 29500764
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity.
Suresh K; D'Alessio F
Crit Care Med; 2019 Sep; 47(9):e788. PubMed ID: 31415322
[No Abstract] [Full Text] [Related]
18. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.
Ji Y; Sy SKB
Cancer Chemother Pharmacol; 2024 Apr; 93(4):273-293. PubMed ID: 38430307
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Reynolds K; Thomas M; Dougan M
Oncologist; 2018 Sep; 23(9):991-997. PubMed ID: 29853659
[TBL] [Abstract][Full Text] [Related]
20. Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Haratani K; Hayashi H; Nakagawa K
BMC Med; 2020 Apr; 18(1):111. PubMed ID: 32312270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
